Questions to Jean-Paul Borg, Scientific Director of IPC
Introduction to research activities with Jean-Paul Borg, Scientific Director of Institut Paoli-Calmettes
What is distinctive about an institute like ours is the combination of research and care in one place.
The goal of the reorganization of our research, effective in 2012, is to bring even closer all players contributing to the advancement of our discipline: the discoverers of the targets of basic research, translational research experts that guide these discoveries to applications, oncologists and personnel that evaluate the efficacy and safety in clinical development of these new treatments and to make available the 80,000 samples of our biobank and the best technology and engineering. In practical terms this also means:
- A new building that houses nearly one hundred researchers from CNRS, INSERM, the IPC and the new Aix-Marseille University.
- A new team dedicated to translational research and evaluation of therapeutic drug candidates.
- New tools such as the platform for preclinical evaluation TrGET ® or the unit dedicated to early clinical trials, ETOH.
- New vocations: project manager, research organizer, research nurse...
- Exploring new avenues of research, such as mechanisms of DNA repair or the relationship between cellular stress and cancer.
- Finally, a new project-based organization that promotes the emergence of innovative approaches in areas of historical expertise of the Institute: hematologic malignancies, breast, digestive and urogenital cancers.
If we want to advance our knowledge in oncology it is imperative that research be closely involved in the care of patients.
This is because research in the IPC is first and foremost determined by the needs of the oncologist and his patient but also because the manner in which the patient responds to treatment is full of information for the researcher, whether he is oriented to fundamental or more applied studies. In this way, when a patient is resistant to treatment, the researcher quickly explores the biological peculiarities of the tumor to identify a potential biomarker associated with this resistance. Once validated, this biomarker will be used by the oncologist to stratify patients and use this treatment only for patients who may benefit from it.
Of course, the strength of the IPC is its scientific and medical excellence and advanced technology but also the constant questioning and the collaborative culture that make possible the continuous back and forth interaction between biology and the clinic.
A new building houses nearly one hundred researchers
Comprehensive Cancer Center
The Marseille SIRIC is a comprehensive cancer center which brings together a critical mass of over 750 scientists and physicians working in state-of-the-art hospitals, Institut Paoli Calmettes (IPC) and the Assistance Publique-Hôpitaux de Marseille (AP-HM) and their associated research centers.